-
Dr. Qu Fajun Showcases Single-Port Robotic Hood Technique for Scarless Prostate Surgery
At the forefront of surgical innovation, Dr. Qu Fajun (Changzheng Hospital) presented a refined interpretation of the Hood technique using a cutting-edge single-port robotic platform. Aiming to elevate prostate cancer…
-
AI-Powered Precision: Dr. Kan Gong Presents Smarter Biopsy Strategies for Prostate Cancer
At the Pujiang Prostate Cancer Academic Conference, Dr. Kan Gong (Peking University First Hospital) introduced an AI-driven diagnostic workflow that enhances prostate cancer precision care—from refined PSAD calculation to advanced…
-
Prof. Xiaojie Bian at ASCO: Chinese Subgroup Analysis of TALAPRO-2 Shows Survival Benefit with TALA + ENZA in mCRPC
Study Overview In the Chinese subgroup of TALAPRO-2, patients with unselected mCRPC who received talazoparib plus enzalutamide showed improved radiographic progression-free survival (rPFS) based on BICR assessment (HR = 0.30;…
-
Precision Therapy in mCRPC: Prof. Shouzhen Chen Highlights Molecular Subtyping Trends
At ASCO and EAU 2025, Professor Shouzhen Chen (Qilu Hospital, Shandong University) shared an in-depth overview of molecular subtyping in mCRPC. He emphasized established targets like HRR and MSI-H, explored…
-
Facing the Frontlines of Prostate Cancer: Insights from Drs. Zhou Liangping, Wang Qifeng, Yong Jia, and Qi Ma
In a thought-provoking panel discussion, leading Chinese experts Drs. Zhou Liangping, Wang Qifeng, Yong Jia, and Qi Ma tackled several pressing issues in prostate cancer care. The conversation spanned diagnostic…
-
Voices from China at ASCO | Professor Biyun Wang：New First-line Treatment Strategy for mTNBC and Research on the Efficacy Prediction of T-DXd for HER2+ Breast Cancer Brain Metastases Presented
At the 2025 ASCO Annual Meeting, multiple cutting-edge oncology studies were presented. Among them were two studies led by Professor Biyun Wang from Fudan University Shanghai Cancer Center. One was a prospective, single-arm phase II clinical trial (Abstract #1101) evaluating the efficacy and safety of camrelizumab in combination with albumin-bound paclitaxel and cisplatin (the AP…
Connecting Medical Expertise through Media
